Preferred for patients with MTHFR mutations (which are common in the general population) and for patients who want the most directly usable form
FDA Pharmacy Compounding Advisory Committee has recommended adding six peptide substances, including BPC-157, TB-500, and MOTS-c, to the FDA's 503A Bulks List
The cost for the signature delivery is incorporated into the price of the product
Reduces Inflammation Acts as a potent anti-inflammatory agent to reduce pain and swelling
Patients in Brooklyn, Queens, Manhattan, the Bronx, Staten Island, Long Island, and surrounding New York communities may discuss personalized BPC-157 therapy options with licensed providers for recovery support, mobility wellness, muscle recovery, exercise recovery, and active lifestyle goals
However, the clinical significance of this is unclear (144)